MedTrace Logo

Quercetin as Possible Supportive Therapy for Mild to Moderate Hyperuricemia

NCT06591767 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2024-10-17

No results posted yet for this study

Summary

Uric acid, a metabolic byproduct of purine degradation in humans, is a known risk factor for conditions such as gout and type 2 diabetes. Research has shown that supplementation with quercetin can significantly reduce plasma uric acid levels in individuals with mild hyperuricemia, potentially mitigating these associated risks.

Conditions

  • Hyperuricemia

Interventions

DIETARY_SUPPLEMENT

Quercetin

200 mg supplemental Quercefit®

COMBINATION_PRODUCT

Berberol K®

Berberine Phytosome® 730 mg \+ MonakoPure® containing 2.9 mg of monacolin K and KA from red yeast rice extract

Sponsors & Collaborators

  • University of Urbino "Carlo Bo"

    collaborator OTHER

  • Liaquat University of Medical & Health Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2024-04-30
Completion
2024-08-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06591767 on ClinicalTrials.gov